Most serotypes of human adenoviruses, except subgroup C viruses such as serotype 2 (Ad2) and Ad5, can grow only to low titers in vitro in human cell lines. To analyze the properties of the replicative cycles of poorly growing Ad serotypes, we compared Ad37 and Ad5 in human A549 cells. In comparison with Ad5, Ad37 showed a slower development of viral-induced cytopathic effects and prolonged cell viability. Furthermore, the maximum yields of progeny viruses were reduced by almost 100-fold. Although the amount of viral DNA and E1A mRNA in infected cells reached comparable levels between these two serotypes, the accumulation of viral late mRNAs and structural proteins in Ad37-infected cells was severely reduced. Overall, our study explains critical steps in the replicative cycle of Ad, which cause serotype-specific restrictions in permissive human cell lines.
Archives of Virology – Springer Journals
Published: Sep 1, 2009
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera